Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 206

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 206
---
 of directors, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. If, following the Business Combination, securities or industry analysts do not publish or cease publishing research or reports about New Profusa, its business, or its market, or if they change their recommendations regarding New Profusa’s securities adversely, the price and trading volume of New Profusa’s securities could decline. The trading market for New Profusa’s securities will be influenced by the research and reports that industry or securities analysts may publish about New Profusa, its business, market or competitors. Securities and industry analysts do not currently, and may never, publish research on New Profusa. If no securities or industry analysts commence coverage of New Profusa, New Profusa’s share price and trading volume would likely be negatively impacted. If any of the analysts who may cover New Profusa change their recommendation regarding New Profusa Common Stock adversely, or provide more favorable relative recommendations about its competitors, the price of New Profusa Common Stock would likely decline. If any analyst who may cover New Profusa were to cease coverage of New Profusa or fail to regularly publish reports on it, New Profusa could lose visibility in the financial markets, which in turn could cause its share price or trading volume to decline. Securities of special purpose acquisition companies that have engaged in a business combination transaction, such as the Business Combination, may experience a material decline in price relative to the share price of the special purpose acquisition company prior to such business combination transaction. As with most initial public offerings of special purpose acquisition companies in recent years, NorthView issued public shares for $10.00 per share upon the closing of the IPO. As with other special purpose acquisition companies, the $10.00 per share price reflected each public share having a right to redeem such share for a pro rata portion of the proceeds held in the Trust Account, which is expected to equal approximately $12.21 per share prior to the Closing. Following the Closing, the outstanding shares of New Profusa Common Stock will no longer have any such 94 redemption right and will be solely dependent upon the fundamental value of New Profusa, which, like the securities of other companies formed through business combination transactions with special purpose acquisition companies in recent years, may be significantly less than $10.00 per share. Following the consummation of the Business Combination, the value of the New Profusa Common Stock will be affected by many factors, including